Board of Directors

Mr. Nick BedfordChairman

Mr. Bedford brings his expertise in business and finance to Zymeworks, after serving as Chairman of the Board of Directors of ActiveState Corporation, up to the time of its acquisition by Sophos UK. Additionally in the past, he has held senior positions at UBS Warburg, including the Frankfurt-based role as Head of German Equities. In this position he oversaw all sales and sales trading of equity products, and was responsible for the merger of UBS Germany's equity business with SBC Warburg. Prior to this he was with UBS' Securities division in Zurich, Tokyo, and London. Mr. Bedford holds a B.Sc. in Civil Engineering from King's College, London University.

Dr. Kerry L. Blanchard Ph.D., M.D.

Dr. Blanchard is currently Eli Lilly & Co.’s Senior Vice-President of Medicines Development Unit and Vice President of Tailored Therapeutics. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982, and an MD in 1985 from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Center, and Harvard Medical School in 1990. Prior to joining Eli Lilly in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. He has played multiple roles in Lilly Research Laboratories including Senior Clinical Research Physician in Program Phase Oncology, Chief Scientific Officer Cancer Discovery, Executive Director of Cancer Discovery & Lilly Systems Biology-Singapore, and Chief Operating Officer/Vice-President of Discovery Research and Vice-President of Integrative Biology. He has served on the Board of Directors of the Lilly Singapore Centre for Drug Discovery and Systems Biology. He is a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, and he serves on the Board of Directors of the Lilly Suzhou Pharmaceutical Company.

Dr. Donald Drakeman Ph.D.

Dr. Drakeman is a Venture Partner at Advent Venture Partners LLP, and holds a Ph.D. from Princeton University and a J.D. from Columbia University. Dr. Drakeman co-founded two international biotech companies focused on monoclonal antibody therapeutics; Medarex, Inc. and Genmab A/S. Under his leadership as CEO, Medarex raised over a billion dollars, formed alliances with multiple pharmaceutical companies, developed numerous therapeutic products, and spun-off Genmab, which completed Europe’s largest biotech IPO to date. In 2009, Medarex was subsequently acquired by Bristol-Myers Squibb for US$2.4 billion. During his 22 years in the biotechnology and pharmaceuticals industry, Dr. Drakeman has overseen the progress of over 30 innovative new medical products for cancer, infectious disease and inflammation from research concepts into clinical trials.

Mr. Haig Farris LL.D.

In 1972, Mr. Farris was one of the co-founding members and partners of the Ventures West Management group of venture capital funds, the largest venture capital pool in western Canada. Venture management experience includes finding, financing and developing high-technology startups and corporate turn-around opportunities. Since 1990, he has been President of Fractal Capital Corp., a private venture capital company financing high technology start-ups and resource service technology companies. As a co-founding investor in Zymeworks, Mr. Farris has been a key part of the growth, expansion and success of the company from inception.

Mr. Farris holds a Bachelor of Arts (Economics & English) from the University of British Columbia, a Law Degree from the University of Pennsylvania Law School and an Honorary Doctor of Laws Degree from UBC.

Mr. Kenneth Galbraith CA

Mr. Ken Galbraith is the Founder and Managing Director of Five Corners Capital. Prior to founding Five Corners Capital in 2013, Mr. Galbraith was a General Partner with Ventures West Capital, where he led led the firm's biotech practice. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 20 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. In 2006, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost $600 million. Previously, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO. He currently serves as a Director of Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics, NeurAxon and Presidio Pharmaceuticals.

Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia and is a Chartered Accountant.

Mr. Noel Hall

Mr. Noel Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-founder, President, and Director of Aspreva Pharmaceuticals, which was acquired by the Galenica Group in January 2008. Prior to Aspreva, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton and served as Head of Global Strategic Planning for the firm’s worldwide pharmaceutical consulting practice. Mr. Hall was the Director of Corporate Affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GlaxoSmithKline PLC. Additionally, Mr. Hall worked in market development with Abbott Laboratories Ltd. and was the regional sales manager with Leo Laboratories Ltd. Mr. Hall holds a B.Sc. degree in Medical Laboratory Science from London University, and currently serves on the board of directors of iCo Therapeutics Inc.

Mr. Amos Michelson MBA

Mr. Amos Michelson was the CEO of Creo Inc. from 1995 to 2005. He joined Creo in 1991 and, prior to his appointment as CEO, served in senior positions including Vice President Business Strategy, Managing Director, and Chairman of the Board. Before joining Creo, Mr. Michelson was the CEO of Opal, Inc., a semi-conductor equipment company, and COO of Optrotech Ltd., a developer and manufacturer of optical and imaging systems for the electronics industry. Mr. Michelson is a past member of the British Columbia Premier’s Technology Council. In 1999, together with Dan Gelbart (the co-founder of Creo Inc.), he was named an Ernst & Young Entrepreneur Of The Year® and in 2005 was recognized as the British Columbia Technology Industry Association’s “Person of the Year”. Mr. Michelson holds an MBA from the Stanford Business School and a BSEE from the Technion, Israel Institute of Technology, and serves on the boards of Kardium Inc., Cogent Health Solutions, IKOMED Technologies Inc., Equicare Health and other companies in the healthcare and technology sectors.

Dr. Ali Tehrani Ph.D.President & CEO, Zymeworks Inc.

Dr. Tehrani is one of Zymeworks' co-founders and currently serves as President and CEO of the company. He has been an integral part of many of the Company's corporate achievements including raising seed and angel financing and overseeing the Company's technical operations and patent filings. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his PhD degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002.

Dr. Tehrani has served on the MITACS Industrial Advisory Board, and BIOTECanada's Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of LifeSciences British Columbia and the Student Biotechnology Network.

Dr. Shermaine Tilley Ph.D., MBA

Dr. Shermaine Tilley is a Managing Partner at CTI Life Sciences Fund, a Montreal-based venture capital fund investing across Canada and the U.S. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the Fund’s investments, including Medicago (acquired by Mitsubishi Tanabe for $357M in 2013) as well as Xagenic and Zymeworks. Prior to joining CTI LSF, Dr. Tilley was Senior VP at Drug Royalty Corporation (now DRI), the world’s first private equity firm exclusively focused on royalty transactions in the biotech/pharma space. Before DRC, Dr. Tilley ran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious diseases for 10 years.

Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the CFA Society of Toronto. She currently sits on the boards of Xagenic, Zymeworks and BIOTECanada, and served as a board observer on Enobia prior to its acquisition by Alexion in 2012 for $1.1B.